Literature DB >> 32875578

Continuous EEG findings in patients with COVID-19 infection admitted to a New York academic hospital system.

Jacob Pellinen1, Elizabeth Carroll1, Daniel Friedman1, Michael Boffa1, Patricia Dugan1, David E Friedman1, Deana Gazzola1, Amy Jongeling1, Alcibiades J Rodriguez1, Manisha Holmes1.   

Abstract

OBJECTIVE: There is evidence for central nervous system complications of coronavirus disease 2019 (COVID-19) infection, including encephalopathy. Encephalopathy caused by or arising from seizures, especially nonconvulsive seizures (NCS), often requires electroencephalography (EEG) monitoring for diagnosis. The prevalence of seizures and other EEG abnormalities among COVID-19-infected patients is unknown.
METHODS: Medical records and EEG studies of patients hospitalized with confirmed COVID-19 infections over a 2-month period at a single US academic health system (four hospitals) were reviewed to describe the distribution of EEG findings including epileptiform abnormalities (seizures, periodic discharges, or nonperiodic epileptiform discharges). Factors including demographics, remote and acute brain injury, prior history of epilepsy, preceding seizures, critical illness severity scores, and interleukin 6 (IL-6) levels were compared to EEG findings to identify predictors of epileptiform EEG abnormalities.
RESULTS: Of 111 patients monitored, most were male (71%), middle-aged or older (median age 64 years), admitted to an intensive care unit (ICU; 77%), and comatose (70%). Excluding 11 patients monitored after cardiac arrest, the most frequent EEG finding was moderate generalized slowing (57%), but epileptiform findings were observed in 30% and seizures in 7% (4% with NCS). Three patients with EEG seizures did not have epilepsy or evidence of acute or remote brain injury, although all had clinical seizures prior to EEG. Only having epilepsy (odds ratio [OR] 5.4, 95% confidence interval [CI] 1.4-21) or seizure(s) prior to EEG (OR 4.8, 95% CI 1.7-13) was independently associated with epileptiform EEG findings. SIGNIFICANCE: Our study supports growing evidence that COVID-19 can affect the central nervous system, although seizures are unlikely a common cause of encephalopathy. Seizures and epileptiform activity on EEG occurred infrequently, and having a history of epilepsy or seizure(s) prior to EEG testing was predictive of epileptiform findings. This has important implications for triaging EEG testing in this population.
© 2020 International League Against Epilepsy.

Entities:  

Keywords:  COVID-19; EEG; clinical neurology; epilepsy monitoring; epilepsy/seizures

Mesh:

Year:  2020        PMID: 32875578     DOI: 10.1111/epi.16667

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  20 in total

1.  EEG Abnormalities and Their Radiographic Correlates in a COVID-19 Inpatient Cohort.

Authors:  Sean T Hwang; Ahmad A Ballout; Anup N Sonti; Amitha Kapyur; Claudia Kirsch; Neeraj Singh; Noah Markowitz; Tung Ming Leung; Derek J Chong; Richard Temes; Steven V Pacia; Ruben I Kuzniecky; Souhel Najjar
Journal:  Neurol Clin Pract       Date:  2022-02

2.  Non-Invasive Multimodal Neuromonitoring in Non-Critically Ill Hospitalized Adult Patients With COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Denise Battaglini; Lavienraj Premraj; Samuel Huth; Jonathon Fanning; Glenn Whitman; Rakesh C Arora; Judith Bellapart; Diego Bastos Porto; Fabio Silvio Taccone; Jacky Y Suen; Gianluigi Li Bassi; John F Fraser; Rafael Badenes; Sung-Min Cho; Chiara Robba
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.086

3.  New-onset refractory status epilepticus as an early manifestation of multisystem inflammatory syndrome in adults after COVID-19.

Authors:  Omar Nawfal; Hassan Toufaili; Georgette Dib; Maya Dirani; Ahmad Beydoun
Journal:  Epilepsia       Date:  2022-03-27       Impact factor: 5.864

Review 4.  Epilepsy and COVID-19: Updated evidence and narrative review.

Authors:  Naoto Kuroda
Journal:  Epilepsy Behav       Date:  2021-01-13       Impact factor: 3.337

5.  Electroencephalographic Abnormalites in SARS-CoV-2 Patients.

Authors:  Stephane Besnard; Clotilde Nardin; Elsa Lyon; Thomas Debroucker; Roxana Arjmand; Raffaella Moretti; Hervé Pochat
Journal:  Front Neurol       Date:  2020-11-26       Impact factor: 4.003

6.  Association of Clinical, Biological, and Brain Magnetic Resonance Imaging Findings With Electroencephalographic Findings for Patients With COVID-19.

Authors:  Virginie Lambrecq; Aurélie Hanin; Esteban Munoz-Musat; Lydia Chougar; Salimata Gassama; Cécile Delorme; Louis Cousyn; Alaina Borden; Maria Damiano; Valerio Frazzini; Gilles Huberfeld; Frank Landgraf; Vi-Huong Nguyen-Michel; Phintip Pichit; Aude Sangare; Mario Chavez; Capucine Morélot-Panzini; Elise Morawiec; Mathieu Raux; Charles-Edouard Luyt; Pierre Rufat; Damien Galanaud; Jean-Christophe Corvol; Catherine Lubetzki; Benjamin Rohaut; Sophie Demeret; Nadya Pyatigorskaya; Lionel Naccache; Vincent Navarro
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 7.  Evaluation and Treatment of Seizures and Epilepsy During the COVID-19 Pandemic.

Authors:  Jacob Pellinen; Manisha Gupte Holmes
Journal:  Curr Neurol Neurosci Rep       Date:  2022-01-26       Impact factor: 6.030

8.  Early Neurorehabilitation and Recovery from Disorders of Consciousness After Severe COVID-19.

Authors:  Lindsey Gurin; Megan Evangelist; Patricia Laverty; Kaitlin Hanley; John Corcoran; Jodi Herbsman; Brian Im; Jennifer Frontera; Steven Flanagan; Steven Galetta; Ariane Lewis
Journal:  Neurocrit Care       Date:  2021-10-05       Impact factor: 3.532

Review 9.  Seizure Management in the Intensive Care Unit.

Authors:  Jane G Boggs
Journal:  Curr Treat Options Neurol       Date:  2021-10-21       Impact factor: 3.598

10.  Altered Mental Status in Patients Hospitalized with COVID-19: Perspectives from Neurologic and Psychiatric Consultants.

Authors:  Daniel Talmasov; Sean M Kelly; Ariane Lewis; Adrienne D Taylor; Lindsey Gurin
Journal:  Harv Rev Psychiatry       Date:  2021 Nov-Dec 01       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.